Using NULISAseq to identify biomarkers linked to postmortem Alzheimer's disease and other neurodegenerative pathologies

Neuropathological validation is critical for establishing peripheral biomarkers of disease pathology. With limited in vivo gold-standards for TDP-43 and Lewy body pathologies, our postmortem findings show potential plasma biomarkers (e.g., pTDP43-409 and DDC) that may act as proxy indicators of these pathologies. The strong association of pTau-217 with AD neuropathology highlights the utility of NULISAseq for biomarker discovery.